Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Opus Genetics Inc IRD

Healthcare Biotechnology
Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1... see more

Current News (NDAQ:IRD)

Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update

GlobeNewswire 6 days ago

Opus Genetics to Present at Upcoming Investor Conferences in March 2026

GlobeNewswire 13 days ago

Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting

GlobeNewswire February 27, 2026

Opus Genetics Announces FDA Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

GlobeNewswire February 25, 2026

Opus Genetics Announces $25 Million Private Placement

GlobeNewswire February 13, 2026

Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026

GlobeNewswire February 2, 2026

Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa

GlobeNewswire January 27, 2026

Opus Genetics Highlights 2025 Progress and Upcoming 2026 Catalysts

GlobeNewswire January 8, 2026

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire December 16, 2025
View More News ››

Opinion & Analysis (NDAQ:IRD)

Biotech with Tenbagger Potential Signs Deal with Chinese Firm

Streetwise Reports February 14, 2018

Let volatility power your micro-cap biotechs

The Life Sciences Report April 28, 2016

Capitalize on comeback stories in micro-cap biotech: Joe Pantginis of ROTH Capital Partners

George S. Mack June 17, 2015
View More Opinion ››

Bullboard Posts (NDAQ:IRD)

RE:FDA PDUFA Date September 28, 2023

And there you have it.   FDA Approval of Nyxol RM, which will be manufactured and sold under the name RYZUMVI by Viatris...
joebravo - September 27, 2023

FDA PDUFA Date September 28, 2023

Not sure why this board has very little following, but this little company with a small float of 21 million shares is about to receive a...
joebravo - September 13, 2023

OCUP....early a.m runner up on NR

You better be looking both ways on this ...... THere is a Shelf Offering on the table   This will come back to bite you real...
Iseneschal - November 24, 2021

added more of this one

using dollar cost averaging ,or DCA,for this one,and yes it was a $600 stock but that was 20 years ago,so glta shareholders.
coolfooldumbguy - February 14, 2020

RE:it's a buy today for me

once $600
Teccing - February 11, 2020

it's a buy today for me

got it this morning at $3.25 per share,it is making a comeback,so glta shareholders.
coolfooldumbguy - February 11, 2020
View more Bullboard ››

dynaCERT Inc.

dynaCERT Inc.

dynaCERT Inc., together with its subsidiaries, engages in the design, engineering, manufacture, testing, and distribution of ...
View More »

Podcasts